Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4

Group 1 - ClearBridge Investments reported a strong but volatile performance in US equities for Q4 2025, with the S&P 500 Index returning 2.7% and the Russell Midcap Growth Index declining 3.7% [1] - The ClearBridge Growth Strategy achieved its third consecutive quarter of outperformance by maintaining a balanced, highly active share approach, capturing early momentum while providing downside protection during rising volatility [1] - The strategy emphasized disciplined portfolio management and opportunistic capital allocation as part of its long-term investment philosophy [1] Group 2 - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is highlighted as a key stock in the ClearBridge Growth Strategy, focusing on therapies for cystic fibrosis [2] - Vertex Pharmaceuticals experienced a one-month return of 1.79% and a 52-week gain of 12.21%, with its stock closing at $463.86 per share and a market capitalization of $118.929 billion on January 9, 2026 [2] - The company benefited from growing optimism around its kidney disease pipeline, contributing positively to the health care sector within the ClearBridge Growth Strategy [3] Group 3 - Vertex Pharmaceuticals delivered $3.08 billion in revenue for Q3 2025, reflecting an 11% growth compared to Q3 2024 [4] - Despite its potential, Vertex Pharmaceuticals is not among the 30 most popular stocks among hedge funds, with 61 hedge fund portfolios holding its stock at the end of Q3 2025, up from 53 in the previous quarter [4] - The analysis suggests that certain AI stocks may offer greater upside potential and carry less downside risk compared to Vertex Pharmaceuticals [4]